Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICVAX Phase I Trial in HIV-infected Patients
NCT07530198Phase 1Recruiting
- Sponsor
- Immuno Cure
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ICVAX in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Immuno Cure. Primary endpoints: Safety of ICVAX and Antigen-specific T Cell Response Induced by ICVAX. Started Mar 2026; status: recruiting.
02
Drugs
ICVAX
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07530198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07530198.